Braveheart Bio, Inc. BRVE
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- -35.34%
- 1 year
- -35.34%
5D -1.56 (-7.64%)
- Market cap
- 1.58B
- EPS (ttm)
- -6.85
- Shares out
- 82.07M
- Forward P/E
- -9.68
- YTD return
- -35.34%
- 1-year return
- -35.34%
- 50-day average
- 21.51
- 200-day average
- 23.43
- Enterprise value
- 1.32B
- Volume
- 1.11M
- Avg volume
- 465.21K
- Open
- 18.68
- Previous close
- 18.53
- Day's range
- 18.24 – 19.50
- 52-week range
- 17.42 – 30.00
- Analysts
- Strong Buy
- Price target
- 45.50 (+136.1%)
- Earnings date
- Feb 9, 2027
Key statistics
- Price / book
- 3.18
- Total cash
- 349.27M
- Total debt
- 515.00K
Fundamental scorecard
3 of 25 checks passed on BRVE’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth No data
- Profitability No data
- Financial health 3 of 5
- Dividend No data
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 40.00
- Target (mean)
- 45.50
- Target (high)
- 49.00
- Strong buy0
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 9, 2027
Expected Feb 9, 2027. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 9, 2027 | Sep 30, 2026 | -0.438 | — | — | — |
| Nov 10, 2026 | Jun 30, 2026 | -0.438 | -0.51 | -0.07 | -16.44% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 20, 2026 | Cantor Fitzgerald | reit | Overweight | Overweight |
About Braveheart Bio, Inc.
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- braveheart.bio
News
Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
Braveheart Bio to Participate in the Jefferies Global Healthcare Conference in London
Braveheart Bio, Inc. (BRVE) Shareholder/Analyst Call Transcript
Braveheart Bio Shares One-Year Heart Drug Data, Plans New Fixed-Dose Trial Hengrui Pharma And Braveheart Bio Report Durable 52-Week HRS/BHB-1893 Benefits In oHCM; Says Data Across Both Forms Of HCM And Preclinical Models Suggest Potential To Address Underlying Pathophysiology Of Disease, Findings Consistent With Reverse-remodeling And Diastolic Benefits; To Host Investor Event And Webcast Today At 4:35 p.m. ET
Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026 Braveheart Bio Announces Late-breaking Presentation Of 52-Week Extension Data For BHB-1893 In Obstructive HCM At The American Heart Association Scientific Sessions, November 6-9; Will Also Host Webinar
Braveheart Bio Announces Upcoming Presentations at the American Heart Association Scientific Sessions 2026
Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026
Braveheart Bio: In Non-Obstructive HCM, The Therapeutic Window Is The Product
Your note
Sign in to keep a note on BRVE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHIMOVITS EREZ | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Aug 6, 2026 | 0 |
| JIANGSU HENGRUI PHARMACEUTICALS CO. LTD. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Aug 6, 2026 | 7,420,090 |
| LUBNER DAVID CHARLES | Director | Purchase | Aug 6, 2026 | 55,555 |
| MURDOCH TRAVIS | Chief Executive Officer | Purchase | Aug 6, 2026 | 8,333,640 |
| RICKEY JAMES PAUL | Chief Financial Officer | Purchase | Aug 6, 2026 | 703,575 |
| VIEHBACHER CHRISTOPHER | Director | Purchase | Aug 6, 2026 | 759,857 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FCPM III Services B.V. | 24.29% | 21,826,024 | 420.59M | Sep 29, 2026 |
| Orbimed Advisors LLC. | 13.55% | 12,175,159 | 234.62M | Sep 29, 2026 |
| a16z Capital Management, L.L.C. | 11.39% | 10,232,420 | 197.18M | Sep 29, 2026 |
| FMR, LLC | 8.44% | 7,585,769 | 146.18M | Sep 29, 2026 |
| Frazier Life Sciences Management, L.P. | 5.86% | 5,267,321 | 101.50M | Sep 29, 2026 |
| Enavate Sciences Gp, LLC | 4.09% | 3,674,656 | 70.81M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SmallCap World Fund Inc | 2.53% | 2,273,151 | 43.80M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.15% | 1,035,862 | 19.96M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 0.87% | 779,600 | 15.02M | Sep 29, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 0.80% | 718,200 | 13.84M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 0.62% | 559,564 | 10.78M | Sep 29, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund | 0.56% | 500,000 | 9.63M | Sep 29, 2026 |
